Navigation Links
InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
Date:5/19/2008

EDT on May 20.

Interested investors and others may participate in the InterMune conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 48122233. A replay of the webcast and teleconference will be available approximately three hours after the call.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 48122233.

To access a live audio webcast of the conference call, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securit
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InterMune Announces Progress on Pirfenidone in IPF
2. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
3. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
4. InterMune Announces Start of Phase 1b Trial of ITMN-191
5. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
6. Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
7. TAP Pharmaceutical Products Inc. Announces Phase 3 TAK-390MR Data Demonstrating Higher Overall Healing Versus Lansoprazole in Patients with Erosive Esophagitis
8. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
9. GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab)
10. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
11. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... has announced the addition of the "Investigation ... report to their offering. Developed by ... of Novolog) is an important drug for the ... aspart, as a fast- acting insulin analog, starts ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; ... MYL ) shareholder vote regarding its planned unsolicited ... Mylan,s offer to Perrigo shareholders have always been, and ... reflection of the value available to Perrigo shareholders, and ... has allowed its shareholders to consider," said Joseph ...
(Date:8/28/2015)... -- The report "Eubiotics Market by Type (Probiotics, Prebiotics, Organic ... & by Region ( North America , ... Rest of the World) - Global Trends and Forecast to ... valued at USD 4.62 Billion in 2014 and is projected ... of 7.4% from 2015 to 2020. Browse ...
Breaking Medicine Technology:China Insulin Aspart Market Report 2010-2019 - Developed by Novo Nordisk 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... Alcoa (NYSE: AA ) today announced a ... CDXS ) and CO2 Solution Inc. (TSX-V: CST), focused ... neutralizing the material to create a commercially viable product. ... world,s leading aluminum producer and will be funded by Alcoa ...
... a new market research report is available in its catalogue: ... http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global ... The Freedonia Group projects world demand for in vitro diagnostic ... in 2014. Based on the advanced nature of medical delivery ...
Cached Medicine Technology:Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 2Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 3Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 4Alcoa Unveils Partnership for Carbon Capture Technology Pilot Test Designed to Turn Emissions Into Beneficial Commercial Products 5Reportlinker Adds World In Vitro Diagnostics Market 2Reportlinker Adds World In Vitro Diagnostics Market 3Reportlinker Adds World In Vitro Diagnostics Market 4Reportlinker Adds World In Vitro Diagnostics Market 5Reportlinker Adds World In Vitro Diagnostics Market 6Reportlinker Adds World In Vitro Diagnostics Market 7Reportlinker Adds World In Vitro Diagnostics Market 8Reportlinker Adds World In Vitro Diagnostics Market 9
(Date:8/28/2015)... ... August 28, 2015 , ... ... Addictions specialist, Dr. James Strawbridge, gives a new approach on solutions in his ... begin with the employer and employees getting together for meaningful group meetings. "This ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... loyalty at a low cost. Personalized with practice contact information and logos, Calendars ... Dental offices can also incorporate Calendars into seasonal mailings, thank you and welcome ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... for those seeking to go deep sea diving. The act of recreational ... decompression sickness; for these reasons, it is vital that all recreational and professional ...
(Date:8/28/2015)... ... August 28, 2015 , ... Popular review ... millionaire dating sites . According to the listings, MillionaireMatch.com bags ... this category. , A spokesperson of Top5MillionaireDatingSites.com said, “This website has ...
(Date:8/28/2015)... ... ... Inc. magazine today ranked PREVENT Life Safety No. 3660 on its ... The list was unveiled online at Inc.com and is the most competitive crop in ... ranks higher on the list than any other company in their industry. , PREVENT ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... generic drugs will get them into consumers, hands quicker, but ... marketing researcher has found. A mathematical model created by ... the chances of getting there first and commanding the best ... Ching is an associate professor of marketing at the University ...
... By Kathleen Doheny HealthDay Reporter , MONDAY, Feb. ... levels of exposure to a substance found in a commonly ... a mental developmental test at 3 years of age than ... at all, new research says. Megan Horton, a postdoctoral ...
... , PHILADELPHIA - So-called barrier sites -- the skin, ... allergens, pollutants, viruses, bacteria, and parasites. Understanding how the ... for understanding such inflammatory diseases as asthma, psoriasis, IBD, ... body,s barriers. David Artis, PhD, professor of ...
... , MONDAY, Feb. 7 (HealthDay News) -- The ... along with the economy, statistics released Monday suggest. ... performed in the country, up five percent from 2009, ... nearly 1.6 million cosmetic surgical procedures and 11.6 cosmetic ...
... PICK: Profiling malaria-causing parasites The majority of ... parasite Plasmodium falciparum . Most at risk are young ... led by Patrick Duffy, at the National Institutes of Health, ... falciparum parasites in such a way that they are ...
... gambling rates continue to rise, University of Missouri researchers ... as an effective and inexpensive way for people with ... Matthew Martens, associate professor of Educational, School and ... his team of researchers received a $172,500 grant ...
Cached Medicine News:Health News:Prenatal Exposure to Pesticides May Harm Kids' Development 2Health News:As Economy Picks Up, So Do Number of Nips & Tucks 2Health News:JCI online early table of contents: Feb. 7, 2011 2Health News:JCI online early table of contents: Feb. 7, 2011 3Health News:JCI online early table of contents: Feb. 7, 2011 4Health News:JCI online early table of contents: Feb. 7, 2011 5Health News:JCI online early table of contents: Feb. 7, 2011 6Health News:JCI online early table of contents: Feb. 7, 2011 7Health News:Simple feedback could be effective therapy for addictive behaviors 2
Caspar Curette, 250 mm, 10"....
Bone Curette, 160 mm...
Bone Currettes...
Townsend is a endocervical stainless-steel curette with round tapered tip....
Medicine Products: